AZD5904-HNMR-28433-MedChemExpress

D5319dat Rev 07/231Product InformationDeoxyribonuclease I bovineRecombinant, expressed in Pichia pastoris , buffered aqueous glycerol solution, ≥ 5,000 units/mg proteinD5319Product DescriptionCAS Registry Number: 9003-98-9Enzyme Commission (EC) Number: 3.1.21.1 Synonyms: DNase I,Deoxyribonucleate 5'-Oligonucleotidohydrolase Molecular mass: ~39 kDaExtinction Coefficient: E 2801% = 11.1Deoxyribonuclease I (DNase I) is an endonuclease that acts on phosphodiester bonds adjacent topyrimidines to produce polynucleotides with terminal 5'-phosphates. A tetranucleotide is the smallest average digestion product. DNase I hydrolyzes single-stranded and double-stranded DNA.•In the presence of Mg 2+ ions, DNase I attacks each strand of DNA independently and the cleavage sites are random.•If Mn 2+ ions are present, both DNA strands are cleaved at approximately the same site.1When chromatin DNA is digested, the reaction rate is restricted by the association of DNA with histones.1 DNase I is found in most cells and tissues. Inmammals, the pancreas is one of the best sources for the enzyme. Pancreatic DNase I was the first isolated DNase.DNase I can be used to remove DNA from protein and nucleic acid samples, and to nick DNA as a first step to incorporate labeled bases into DNA.This recombinant bovine DNase I is a glycoprotein, produced without the addition of any animal-derived materials. Several theses 2 and dissertations 3-7 have cited use of product D5319 in their protocols.ActivatorsDNase I has an absolute requirement for divalent metal cations:• Mg 2+ is the most commonly used divalent cation.8,9•Mn 2+, Ca 2+, Co 2+, and Zn 2+ will also activate DNase I.8-10A concentration of 5 mM Ca 2+ will stabilize DNase I against proteolytic digestion. 0.1 mM Ca 2+ is needed to reduce the rate of inactivation by one-half.11Inhibitors•2-Mercaptoethanol (the reduced enzyme is inactive, but can be reactivated in the presence of Ca 2+ or Mg 2+ ions)10 • Chelators (such as EDTA) • Sodium dodecyl sulfate (SDS)12 •Actin 13There is no single general inhibitor specific for DNase I.2 Citrate inhibits Mg 2+-activated DNase I, but not Mn 2+-activated DNase I.Optimal pHThe optimal pH of DNase I activity is dependent on the divalent ion present. In the presence of both Mg 2+ and Ca 2+, the optimal pH is between 7-8, while in the absence of Ca 2+, the optimal pH is between 5.5-6.0.14Precautions and DisclaimerThis product is for R&D use only. Not for drug,household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.© 2015-2023 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. D5319dat Rev 07/23 DT,GCY,LS,RBG,RC,MAM2ProductThis product is supplied as a solution in 4 mg/mL glycine (pH 5.0), 5 mM calcium acetate, and 50% glycerol.Specific activity: ≥ 5,000 units/mg proteinUnit definition: One unit will produce a change in A 260 of 0.001 per minute per mL at pH 5.0 at 25 °C using DNA, Type I or III, as the substrate. This enzyme assay reaction is performed in 83 mM acetate buffer (pH 5.0), at 25 °C, containing 4.2 mM Mg 2+, in a 3 mL reaction.ImpuritiesProtease: None Detected RNase: None detectedStorage/StabilityThis product retains activity for at least two years when stored at –20 °C.References1. Sambrook, J. et al ., Molecular Cloning: ALaboratory Manual , 2nd edition. Cold Spring Harbor Laboratory Press (Cold Spring Harbor, New York, USA), Vol. 2, p. 5.83 (1989). 2. Schöftner, Leonie Christine, "Development of ahuman 3D skin model to study cutaneous T cells". University of Salzburg, M.Sc. thesis, pp. 18, 21 (2021). 3. Alsiwiehri, Naif, "Identification andcharacterisation of novel cancer testis antigens in human cancer cells". Bangor University, Ph.D. dissertation, p. 35 (2017). 4. Deans, Jonathan Robert, "The Role of NuclearReceptors in Tissue-Specific Gene Expression: The Impact of Genetic Variation on DNA Binding". University of California Riverside, Ph.D. dissertation, p. 34 (2017). 5. Hempel, Heidi Anne, "The role of mast cells inprostate cancer initiation and recurrence". Johns Hopkins University, Ph.D. dissertation, p. 55 (2017). 6. Wu, Zhiyuan, "Immunophenotyping ofColorectal Cancer Reveals a Reduction of CD73 Expression on Tumor-Infiltrating Lymphocytes". Friedrich-Alexander-Universität Erlangen-Nürnberg, Dr. med. dissertation, p. 9 (2021).7. Hinterdobler, Julia Michaela, "Linkinginflammation and atherosclerosis – novel mechanistic insights into how vascular inflammation fuels progression ofatherosclerosis". Technischen UniversitätMünchen, Dr. rer. nat. dissertation, p. 31 (2022). 8. Weir, A. F., Methods Mol. Biol ., 16, 1-6 (1993). 9. Weir, A. F., Methods Mol. Biol ., 16, 7-16 (1993). 10. Price, P. A. et al ., J. Biol. Chem ., 244(3),929-932 (1969). 11. Price, P. A., et al ., J. Biol Chem ., 244(3),917-923 (1969). 12. Liao, T.-H., J. Biol. Chem ., 250(10), 3831-3836(1975). 13. Love, J. D., and Hewitt, R. R., J. Biol. Chem .,254(24), 12588-12594 (1979). 14. Lazarides, E., and Lindberg, U., Proc. Natl. Acad.Sci. USA , 71(12), 4742-4746 (1974).NoticeWe provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve ourcustomers of their own responsibility for checking the suitability of our products for the envisaged purpose. The information in this document is subject to change without notice and should not be construed as acommitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.Technical AssistanceVisit the tech service page at /techservice .Terms and Conditions of UseWarranty, use restrictions, and other conditions of sale may be found at /terms .Contact InformationFor the location of the office nearest you, go to /offices .。

25g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11116
Fmoc-(2-氯苄氧基羰基)赖氨酸
Fmoc-Lys(2-Cl-Z)-OH
133970-31-7
25g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11078
Fmoc-N-甲基-D-亮氨酸
Fmoc-D-N-Me-Leu-OH
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11079
N-叔丁氧羰基-N-甲基-D-苯丙氨酸二环己胺盐
Boc-D-N-Me-Phe.DCHA
102185-45-5
25g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11002
2-(叔-丁氧基碳酰胺)-2-苯乙腈
Boc-ON
58632-95-4
25g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11120
N,N'-双芴甲氧羰基-L-赖氨酸
Fmoc-Lys(Fmoc)-OH
78081-87-5
100g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11110
Fmoc-L-异亮氨酸
Fmoc-Ile-OH

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Mar.-29-2018Print Date:Mar.-29-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :AZD5904Catalog No. :HY-111341CAS No. :618913-30-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:C10H12N4O2SMolecular Weight:252.29CAS No. :618913-30-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

rx-ADC抗体偶联简介——MMAF 一甲基澳瑞他汀F CAS745017-94-1MMAF, a synthetic derivative of dolastatin 10, belongs to a class of compounds called aurastatins and is a potent cellular inhibitor. It has been used as a payload for developing drug conjugates (ADC) targeting ADC antibodies.MMAF的作用是抑制微管蛋白聚合，破坏细胞内的微管网络。

微管对包括细胞分裂在内的各种细胞过程至关重要，破坏它们会导致细胞周期停滞，*终导致细胞死亡。

通过将MMAF连接到靶向**细胞表面特定抗原的单克隆抗体上，ADC可以选择性地将这种细胞*性有效载荷传递到**细胞，同时保留健康组织。

这种有针对性的方法旨在提高药物的**效果，同时降低全身*性。

中文名称：一甲基澳瑞他汀F英文名称：MMAFCAS：745017-94-1分类：ADC抗体PEG分子量：1/2/3/2000/3000/4000/5000/200000状态：固体/粉末/溶液产品规格：mg保存：冷藏储藏条件：-20℃储存时间：1年用途：科研温馨提醒：仅供科研，不能用于人体实验相关：Azido-PEG3-Val-Cit-PAB-OHAzido-PEG3-Val-Cit-PAB-PNPBCN-PEG3-Val-CitBCN-PEG3-VC-PFPEsterAuristatinEVal-Cit-PAB-MMAEMC-MMAFCabazitaxel7-O-(Amino-PEG4)-paclitaxelAzido-PEG5-Ala-Ala-Asn-PABFmoc-PEG3-Ala-Ala-Asn(Trt)-PABAzido-PEG4-Ala-Ala-Asn(Trt)-PABFmoc-PEG3-Ala-Ala-Asn(Trt)-PAB-PNP微管抑制剂Fmoc-Val-Cit-PAB-MMAEAmino-PEG4-Val-Cit-PAB-MMAEendo-BCN-PEG4-Val-Cit-PAB-MMAE卡利奇霉素美登醇瑞禧WFF.2023.9。